https://www.selleckchem.com/pr....oducts/sovleplenib-h
898, .001). Discriminant validity was confirmed via a receiver operating characteristic ( .001, area under the curve = 0.70. The NOSE-Perf scale was able to distinguish among all 3 study groups ( .001) and between NSP and nasal obstruction ( = .024). When used alone, the NOSE scale could not discriminate between NSP and nasal obstruction ( = .545). The NOSE-Perf scale is a validated and reliable clinical assessment tool that can be applied to adult patients with NSP. The NOSE-Perf scale is a validated and r
Curtir
Comentario
Compartilhar
